Enzalutamide treatment for the whole spectrum of CRPC

Enzalutamide treatment for the whole spectrum of CRPCEnzalutamide treatment for the whole spectrum of CRPC, Published online: 21 September 2018; doi:10.1038/s41585-018-0090-1The FDA recently expanded the indication for enzalutamide for the treatment of all men with metastatic and nonmetastatic castration-resistant prostate cancer on the basis of the PROSPER trial. Now that both disease states can have the same treatment, the need to thoroughly identify metastatic lesions is questioned.
Source: Nature Reviews Urology - Category: Urology & Nephrology Authors: Source Type: research